AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04453462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic carpal tunnel release under local direct median nerve block
Description: local direct median nerve block is performed by surgeon using the 1%xylocaine with adrenaline 12 mL(5 mL subcutaneous at incision site and 7 mL over median nerve) (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
Study NCT04453462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic carpal tunnel release under brachial plexus block
Description: brachial plexus block under ultrasound-guided is performed by experienced single anesthesiologist using the 1%xylocaine with adrenaline 15 mL (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
Study NCT02512484 — intervention group
Intervention type: PROCEDURE
Intervention: venepuncture, sputum collection, xray
Description: venepuncture, sputum collection, xray
Study NCT03390842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: Oral suspension
Study NCT03390842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study NCT02679963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Study NCT02679963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02030899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cage fusion
Description: Randomized selection of surgery type
Study NCT02030899 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plate fusion
Description: Randomized selection of surgery type
Study NCT01566084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Slow sodium tablets
Description: The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
Study NCT01566084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: Placebo tablets are administered to maintain the low sodium condition.
Study NCT03835793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAC-score
Description: Testing for possible unfavourable health effects of early surgical menopause
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M
Study NCT02656225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ejiao compound
Description: 20ml,twice daily, orally after breakfast Duration:4 weeks
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection Q6M
Study NCT03229018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Voxel size
Description: 200 μm and 300 μm Voxel Sizes
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid 5 mg administered intravenously
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 5 mg administered intravenously
Study NCT00594347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumo 23
Description: Vaccine (Pneumo 23)
Study NCT00594347 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: Vaccine (Prevnar)
Study NCT03839303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infra-zygomatic Mini Implant Supported Appliance
Description: 1. leveling and alignment of the four maxillary incisors~2. infra zygomatic mini-implant will be placed bilaterally~3. wire frame work that is designed resembling the inner bow of headgear will be adapted to the upper arch~4. a heavy arch wire engaging the 4 incisors will be attached to the wire frame work~5. orthopedic force will be delivered from the mini-implants to the wire frame work
Study NCT03839303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high pull head gear
Description: 1. acrylic maxillary splint is made with flying tubes~2. high pull head gear is adapted to be inserted in the flying tubes
Study NCT02656225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niferex
Description: one tablet,once daily, orally after breakfast Duration:4 weeks
Study NCT01020734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT02462642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brahmi
Description: Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
Study NCT02462642 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
Study NCT02462642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brahmi
Description: Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
Study NCT01020734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT01176916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromasin (exemestane)
Description: the dosage, frequency and duration base on the LPD approved by SFDA.
Study NCT04515966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Injection [Solu-Medrol]
Description: A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine will be injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
Study NCT04515966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wrist splint
Description: A standard wrist splint
Study NCT00759070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + emtricitabine + efavirenz
Description: Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)~+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily
Study NCT01020734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT01020734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT01020734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT02462642 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules - Dry starch filled in identical hard gelatin capsules
Study NCT05829785 — intervention group
Intervention type: DEVICE
Intervention: Near-infrared spectroscopy monitor
Description: tissue oxygen saturation monitoring combined with vascular occlusion test
Study NCT02013258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal oxytocin
Description: This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
Study NCT00759070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + emtricitabine + lopinavir/ritonavir
Description: Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
Study NCT02500186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luseogliflozin
Description: Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
Study NCT01020734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT01020734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT02013258 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
Study NCT02561767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow-derived mesenchymal stem cells
Description: BM-MSCs is harvested from third-party health volunteer donors.
Study NCT02561767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline as placebo of MSCs
Study NCT02561767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Induction therapy (ATG or Basiliximab)
Description: ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
Study NCT02561767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction therapy (ATG or Basiliximab)
Description: ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
Study NCT02561767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maintenance therapy (Low-dose CNI + MPA + steroids)
Description: Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
Study NCT01789177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry
Description: Patients will be provided with plastic, disposable incentive spirometers postoperatively
Study NCT01789177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative chest physiotherapy
Description: Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
Study NCT02561767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (Low-dose CNI + MPA + steroids)
Description: Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
Study NCT02366364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral administration of placebo consumption on Day 1
Study NCT02366364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 375 mg
Description: Single oral administration of 375 mg consumption on Day 1
Study NCT02366364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 500 mg
Description: Single oral administration of 500 mg consumption on Day 1
Study NCT02366364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 750 mg
Description: Single oral administration of 750 mg consumption on Day 1
Study NCT02745145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abituzumab 1500 mg
Description: Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
Study NCT02745145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abituzumab 500 mg
Description: Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
Study NCT02745145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
Study NCT00710125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPX-150 for Injection
Description: Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
Study NCT01757158 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cs-131 brachytherapy seeds
Description: Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
Study NCT00561626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat diet followed by low fat diet
Description: High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
Study NCT00561626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low fat diet followed by high fat diet
Description: Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
Study NCT02844062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-EGFRvIII CAR T cells
Description: CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
Study NCT02844062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 250 mg/m\^2 d1-3
Study NCT02844062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/m\^2 d1-3
Study NCT02338232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT00186953 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Optison
Description: Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m\^2 and escalated at 0.15 ml/m\^2 increments, to 0.275 ml/m\^2 and 0.425ml/m\^2 and 0.500ml/m\^2. We will now continue to escalate the dose of Optison at 0.300ml/m\^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer.
Study NCT03826368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Hemp-derived botanical dietary supplement
Description: Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
Study NCT01832584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RGC
Study NCT01832584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02500186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal containing different carbohydrate ratio and GI value
Description: High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
Study NCT03092050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Mindfulness
Description: This is a behavioral intervention using guided imagery and mindfulness techniques.
Study NCT03092050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Discussion
Description: This is a behavioral intervention that involves discussion and group support.
Study NCT03308188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-health program
Description: The Goalistics Chronic Pain Management Program, referred to as the E-health program in EMPOWER, was developed from cognitive, behavioral, interpersonal, and self-management interventions with demonstrated efficacy in traditional face-to-face or group settings. It is patient-centered, having been developed based on substantial input from people with chronic pain and chronic pain professionals.
Study NCT03778086 — intervention group
Intervention type: PROCEDURE
Intervention: gonioscopy
Description: gonioscopic observation and grading of iridocorneal angle
Study NCT03686969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octanorm
Description: Octanorm 0.5g/kg/week
Study NCT03686969 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01044563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing training
Description: Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
Study NCT03371888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma intramuscular injections
Description: A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.
Study NCT03371888 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: 0,9% NaCl intramuscular injections
Description: A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
Study NCT01789177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chest physiotherapy
Description: Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
Study NCT01651000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTAP101 30 μg capsules
Description: CTAP101 30 μg capsule taken daily at bedtime.
Study NCT01651000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill to CTAP101 30 μg capsules
Description: Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
Study NCT01651000 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill to CTAP101 30 μg capsules
Description: Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
Study NCT01044563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management
Description: Cognitive reconstructive strategies for stress management
Study NCT00560755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad®
Description: ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.
Study NCT00769119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg, oral tablet, twice daily for 28 days
Study NCT00769119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x Matched placebo, oral tablet, twice daily for 28 days
Study NCT03696680 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FSRT Stereotactic radiation therapy
Description: For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days
Study NCT02024178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Study NCT02147873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: birinapant
Study NCT02147873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Study NCT02147873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Study NCT04663490 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to Lymphocyte Ratio
Description: Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
Study NCT06770166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiological serum mouthwash
Description: Physiological serum contains sodium chloride : 0.009 g/ml, sodium 154 (mEq/I), chloride 154 (mEq/I)\].
Study NCT06770166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine mouthwash contains 0.12% chlorhexidine digluconate and 0.15% benzydamine hydrochloride.
Study NCT06770166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chamomile mouthwash
Description: Chamomile mouthwash contains 10% chamomile in physiological serum.
Study NCT03232333 — intervention group
Intervention type: DEVICE
Intervention: Biologic wound graft
Description: Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
Study NCT01488513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sphingosine kinase-2 inhibitor ABC294640
Description: Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
Study NCT02721953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butyrate
Description: Butyrate
Study NCT02721953 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01395290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 20.000 IU per week, oral
Study NCT02147873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04485585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9006-1
Description: * Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose